menu
    • menu
    [{"orgOrder":0,"company":"GNT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nelonemdaz","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GNT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nelonemdaz","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GNT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Salfaprodil","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GNT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Salfaprodil","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GNT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Salfaprodil","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GNT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GNT Pharma \/ Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"GNT Pharma \/ Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by GNT Pharma

    Menu

    GNT Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GNT Pharma

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            GNT Pharma

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelonemdaz

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated w...

                            Details : Nelonemdaz (neu2000KWL) is a multi-target neuroprotectant acting as both a moderate NR2B-selective NMDA receptor antagonist and a potent spin trapper that ameliorates both fast NMDA receptor-mediated neuronal death and the delayed free-radical mediated b...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2022

                            Lead Product(s) : Nelonemdaz

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GNT Pharma

                            South Korea arrow
                            ACI Convention
                            Not Confirmed

                            GNT Pharma

                            South Korea arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salfaprodil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

                            Details : Salfaprodil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 10, 2021

                            Lead Product(s) : Salfaprodil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GNT Pharma

                            South Korea arrow
                            ACI Convention
                            Not Confirmed

                            GNT Pharma

                            South Korea arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelonemdaz

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz for Acute Ischemic Stroke Pat...

                            Details : In this study, the addition of nelonemdaz to surgical blood clot removal improved a patient’s chances of returning to functional independence 90 days later.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 14, 2020

                            Lead Product(s) : Nelonemdaz

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GNT Pharma

                            South Korea arrow
                            ACI Convention
                            Not Confirmed

                            GNT Pharma

                            South Korea arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salfaprodil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients

                            Details : Salfaprodil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Arrest.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 29, 2018

                            Lead Product(s) : Salfaprodil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GNT Pharma

                            South Korea arrow
                            ACI Convention
                            Not Confirmed

                            GNT Pharma

                            South Korea arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salfaprodil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)

                            Details : Salfaprodil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 13, 2016

                            Lead Product(s) : Salfaprodil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth